Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsWAR:RVU -2.09%66 Quick Ratio is 2.23 as of Mar. 2026, which is 29% below its 10-year median of 3.16. GuruFocus rates WAR:RVU with a GF Score™ of 66/100 and a GF Value™ of zł45.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Ryvu Therapeutics ranks worse than 62.58% on this metric.
Ryvu Therapeutics has a quick ratio of 2.23. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ryvu Therapeutics's Quick Ratio or its related term are showing as below:
WAR:RVU'
s Quick Ratio Range Over the Past 10 Years
Min: 1.77 Med: 3.16 Max: 9.05
Current: 2.23
During the past 13 years, Ryvu Therapeutics's highest Quick Ratio was 9.05. The lowest was 1.77. And the median was 3.16.
WAR:RVU's Quick Ratio is ranked worse than 62.58% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs WAR:RVU: 2.23
Ryvu Therapeutics (WAR:RVU) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ryvu Therapeutics Quick Ratio Related Terms
Ryvu Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RVU vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Ryvu Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (WAR:RVU) has a Quick Ratio of 2.23 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ryvu Therapeutics and its competitors. This is 29% below median its historical median of 3.16. Over the past decade, Ryvu Therapeutics' Quick Ratio has ranged from 1.77 to 9.05. According to the industry distribution chart, Ryvu Therapeutics ranks #883 out of 1411 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Ryvu Therapeutics' Quick Ratio too high?
Ryvu Therapeutics' current Quick Ratio of 2.23 is 29% below median its 10-year median of 3.16. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 9.05. The Biotechnology industry median Quick Ratio is 3.59. Ryvu Therapeutics' value of 2.23 is 37.9% below this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #883 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #883 out of 1411 companies for Quick Ratio. This places Ryvu Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.59. Ryvu Therapeutics' value of 2.23 is 37.9% below this benchmark. Historically, Ryvu Therapeutics' own Quick Ratio has ranged from 1.77 to 9.05 over the past decade. While the company's 10-year median is 3.16 vs. the industry median of 3.59, Ryvu Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Quick Ratio of 2.23 is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Quick Ratio is 2.23, which is 29% below median its own 10-year median of 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł14.98 — trading 67.3% below its estimated fair value. The current Quick Ratio is 2.23, which is 29% below median its 10-year median of 3.16 and 37.9% below the Biotechnology industry median of 3.59. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Quick Ratio is 2.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for WAR:RVU:
Quick Ratio: 2.23 (29% below median its 10-year median of 3.16)
GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
Industry Position: 37.9% below the Biotechnology median (#883 of 1411)
No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for WAR:RVU
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RVU has been successfully added to your 
